V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210035102 | 210013283 | 1.6 | 66.5 | Palliative (P) | 2019-11-09 | 2019-11-10 | Ofatumumab Loading | 2 | N | 210039734 | TAMIGA TRIAL |
| 210035103 | 210013285 | null | 63 | Palliative (P) | 2014-06-12 | 2014-06-16 | DAUNORUBICIN + VINCRISTINE | Y | Y | 210039746 | CISPLATIN |
| 210035104 | 210013290 | 1.74 | null | Curative (C) | 2016-02-04 | 2016-03-14 | BEAM | null | N | 210039757 | GEMCARBO |
| 210035105 | 210013297 | 0 | 82 | Curative (C) | 2019-03-08 | 2019-03-08 | Cytarabine intrathecal | N | N | 210039787 | BCG |
| 210035106 | 210013315 | 1.58 | 93 | Curative (C) | 2016-12-28 | 2016-12-28 | CARBO + ETOPOSIDE + VINCRISTINE | Y | N | 210039899 | TAMIGA TRIAL |
| 210035107 | 210036186 | null | 78 | Curative (C) | 2014-11-29 | 2014-12-04 | Maintenance Therapy ALL | N | N | 210039963 | CISPLATIN + ETOPOSIDE |
| 210035108 | 210013347 | null | 50 | Curative (C) | 2016-07-22 | 2016-11-30 | Nilotinib | N | null | 210040057 | CARBOPLATIN + LOMUSTINE + VINCRISTINE |
| 210035109 | 210013358 | 1.68 | null | null | 2015-12-11 | 2015-12-29 | Cyclophos + Dex + Lenalidomide | N | null | 210040136 | DOXORUBICIN |
| 210035110 | 210013378 | null | 77 | Palliative (P) | 2016-04-05 | 2016-04-26 | Cetuximab + Radiotherapy Maint | N | null | 210040336 | TAMIGA TRIAL |
| 210035111 | 210013381 | 1.69 | 64.1 | Palliative (P) | 2016-03-10 | 2016-07-08 | Packer Induction Vincristine + RT | Y | N | 210040383 | RMS 2005 TRIAL |
| 210035112 | 210022393 | 1.65 | 135 | Curative (C) | 2017-03-22 | 2017-10-15 | Eribulin | N | N | 210040419 | BEVACIZUMAB + LOMUSTINE |
| 210035113 | 210031489 | 1.85 | null | Adjuvant (A) | 2010-11-02 | 2013-12-02 | BUSULFAN + FLUDARABINE + METHOTREXATE | Y | N | 210040494 | DARATUMUMAB |
| 210035114 | 210013417 | 1.57 | 72 | Curative (C) | 2017-09-22 | 2017-11-04 | Cytarabine intrathecal | 1 | N | 210040628 | ICE |
| 210035115 | 210022420 | 1.52 | null | Curative (C) | 2017-02-05 | 2017-03-15 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | N | 210040696 | ICE |
| 210035116 | 210013433 | 1.65 | 10.8 | Curative (C) | 2016-12-08 | 2016-12-09 | Abiraterone | N | N | 210040699 | SIOP |
| 210035117 | 210013441 | 0.85 | 52.3 | Curative (C) | null | 2014-02-16 | IPILIMUMAB + NIVOLUMAB | 02 | Y | 210040728 | DOXORUBICIN |
| 210035118 | 210022437 | 1.77 | 38 | Palliative (P) | 2016-01-28 | 2016-01-31 | ICE (no GCSF) | N | N | 210040880 | BEVACIZUMAB + IRINOTECAN |
| 210035119 | 210013482 | 0 | null | Disease modification (D) | 2018-03-12 | 2018-06-15 | CVP | 2 | Y | 210040958 | ABVD |
| 210035120 | 210013491 | 0 | 90.5 | Curative (C) | 2014-07-26 | 2014-08-30 | IGEV R | 02 | null | 210041021 | BR14 TRIAL |
| 210035121 | 210013507 | 1.72 | 98.2 | Curative (C) | 2016-09-22 | 2016-09-22 | FLAG | N | null | 210041101 | IDARUBICIN |
| 210035122 | 210013513 | 1.74 | 109.85 | Curative (C) | 2015-04-14 | 2015-04-24 | Cytarabine Intrathecal (any age) | 02 | null | 210041122 | CAPECITABINE |
| 210035123 | 210013518 | 1.71 | null | Curative (C) | 2017-11-23 | 2017-11-23 | Capecitabine + Oxaliplatin 21day | N | N | 210041191 | BEVACIZUMAB + TEMOZOLOMIDE |
| 210035124 | 210013527 | 1.64 | 54.7 | Palliative (P) | 2019-05-06 | 2019-05-06 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE | N | N | 210041199 | AML17 TRIAL |
| 210035125 | 210013547 | 0.85 | null | Palliative (P) | 2016-09-23 | 2016-09-30 | Epirubicin | N | N | 210041346 | REGORAFENIB |
| 210035126 | 210013549 | 1.64 | 84.6 | Curative (C) | 2016-09-30 | 2016-11-09 | Gemcitabine weekly | Y | N | 210041357 | CARBOPLATIN + PACLITAXEL |
| 210035127 | 210022480 | 1.75 | 100 | Curative (C) | 2014-11-26 | 2014-12-04 | Carboplatin + Pemetrexed | N | N | 210041423 | TAMIGA TRIAL |
| 210035128 | 210033674 | 1.64 | 118.3 | Adjuvant (A) | 2015-05-02 | 2015-11-15 | CNS LGG Irinotecan & Bevacizumab | N | N | 210041470 | SIOP |
| 210035129 | 210022496 | 1.89 | 18.1 | Palliative (P) | 2015-06-19 | 2015-07-22 | IMMUNOGLOBULIN | 02 | N | 210041630 | ALL |
| 210035130 | 210022508 | 1.88 | 117.5 | Disease modification (D) | 2019-05-01 | 2019-11-14 | Ofatumumab Weekly | N | null | 210041817 | FLUDARABINE + MELPHALAN |
| 210035131 | 210022512 | null | 83.5 | Disease modification (D) | null | 2016-04-06 | Cyclophosphamide High Dose | null | null | 210041854 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 210035132 | 210013631 | 0 | 65.5 | Curative (C) | 2016-02-24 | 2016-02-24 | Carboplatin + Paclitaxel (weekly) | 2 | N | 210041861 | CYTARABINE |
| 210035133 | 210013644 | null | 82.6 | Curative (C) | 2018-02-28 | 2018-04-24 | CLL210 TRIAL | null | null | 210041983 | OBINUTUZUMAB |
| 210035134 | 210022531 | 1.73 | 65.9 | Curative (C) | 2016-05-24 | 2016-09-23 | ALL Int Guide B Int Maint Ph III | null | N | 210042069 | VINORELBINE |
| 210035135 | 210013663 | 1.81 | null | Curative (C) | 2017-01-20 | 2017-01-20 | AML17 TRIAL | 02 | N | 210042133 | LENALIDOMIDE |
| 210035136 | 210013668 | 0 | null | Disease modification (D) | 2018-03-12 | 2018-03-12 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | N | Y | 210042147 | CYTARABINE + ETOPOSIDE |
| 210035137 | 210013673 | 1.91 | 70.2 | Curative (C) | 2018-09-05 | 2018-12-05 | Phase 2 Induction (ALL) | 2 | N | 210000284 | RUXOLITINIB |
| 210035138 | 210022543 | 0 | 52.1 | null | 2019-11-19 | 2019-12-12 | Nilotinib | N | N | 210004103 | UKALL2003 |
| 210035139 | 210022549 | null | 99.7 | Palliative (P) | 2018-06-27 | 2018-07-11 | Bortezomib (weekly) | N | null | 210008796 | UKALL2003 |
| 210035140 | 210022554 | 1.7 | null | Curative (C) | 2017-11-09 | 2017-11-09 | Bevacizumab + Irinotecan | N | N | 210011848 | SUNITINIB |
| 210035141 | 210022555 | 1.83 | 98.9 | null | 2019-06-23 | 2019-07-01 | CLARITY Trial | N | null | 210012655 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210035142 | 210013709 | 1.71 | 91.2 | Curative (C) | 2018-05-15 | 2018-12-19 | Alemtuzumab + Cyclophos TBI Allo | N | null | 210021324 | IDARUBICIN |
| 210035143 | 210013714 | 1.82 | 99.2 | Disease modification (D) | 2017-12-30 | 2018-02-26 | CISPLATIN + ETOPOSIDE | 02 | N | 210021743 | AML18 TRIAL |
| 210035144 | 210013722 | null | 102.7 | Curative (C) | 2016-08-04 | 2016-08-06 | Nilotinib | 2 | N | 210022095 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210035145 | 210022576 | 1.87 | 88 | Disease modification (D) | 2017-10-04 | 2017-10-04 | DAUNORUBICIN + VINCRISTINE | N | N | 210023716 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210035146 | 210022588 | 1.78 | 27.5 | Neo-adjuvant (N) | 2013-07-25 | 2016-11-16 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 210025389 | CYCLOPHOSPHAMIDE + CYTARABINE + ETOPOSIDE + METHOTREXATE + NELARABINE |
| 210035147 | 210022595 | 1.68 | 82.3 | Curative (C) | 2019-01-30 | 2019-02-21 | PENTOSTATIN + RITUXIMAB | N | null | 210026674 | CYTARABINE HD + METHOTREXATE HD |
| 210035148 | 210013775 | 0 | 112.8 | Curative (C) | 2019-09-19 | 2019-09-27 | Cytarabine intrathecal | N | N | 210027899 | LENALIDOMIDE |
| 210035149 | 210013781 | null | 83.4 | null | 2019-12-11 | 2019-12-19 | CAV | 2 | N | 210028000 | GDP R |
| 210035150 | 210013782 | null | 35.5 | Palliative (P) | 2015-09-11 | 2015-09-26 | MELPHALAN | N | N | 210028065 | ESHAP R |
| 210035151 | 210013786 | 1.69 | null | Curative (C) | 2018-04-20 | 2018-04-24 | BR14 TRIAL | Y | N | 210028705 | ICE-R |